{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T22:44:00Z","timestamp":1774392240989,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Novartis Pharmaceuticals"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.breast.2013.02.003","type":"journal-article","created":{"date-parts":[[2013,3,14]],"date-time":"2013-03-14T13:47:28Z","timestamp":1363268848000},"page":"405-410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Everolimus in hormone receptor\u2013positive advanced breast cancer: Targeting receptor-based mechanisms of resistance"],"prefix":"10.1016","volume":"22","author":[{"given":"Mikhail I.","family":"Shtivelband","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2013.02.003_bib1","series-title":"Cancer facts and figures","author":"American Cancer Society","year":"2012"},{"issue":"7","key":"10.1016\/j.breast.2013.02.003_bib2","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.5858\/134.7.e48","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version)","volume":"134","author":"Hammond","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.breast.2013.02.003_bib3","series-title":"Diseases of the breast","first-page":"489","article-title":"Staging of breast cancer","author":"Harris","year":"2010"},{"issue":"4","key":"10.1016\/j.breast.2013.02.003_bib4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/bcr2607","article-title":"Breast cancer prognostic classification in the molecular era: the role of histological grade","volume":"12","author":"Rakha","year":"2010","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.breast.2013.02.003_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1023\/A:1020299707510","article-title":"Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database","volume":"76","author":"Anderson","year":"2002","journal-title":"Breast Cancer Res Treat"},{"issue":"9472","key":"10.1016\/j.breast.2013.02.003_bib6","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","author":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG)","year":"2005","journal-title":"Lancet"},{"issue":"9036","key":"10.1016\/j.breast.2013.02.003_bib7","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0140-6736(96)05023-4","article-title":"Ovarian ablation in early breast cancer: overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group","volume":"348","year":"1996","journal-title":"Lancet"},{"issue":"9574","key":"10.1016\/j.breast.2013.02.003_bib8","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0140-6736(07)60778-8","article-title":"Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials","volume":"369","author":"Cuzick","year":"2007","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.breast.2013.02.003_bib9","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.breast.2013.02.003_bib10","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1677\/erc.0.0060187","article-title":"Biology of aromatase inhibitors: pharmacology\/endocrinology within the breast","volume":"6","author":"Miller","year":"1999","journal-title":"Endocr Relat Cancer"},{"issue":"Suppl. 4","key":"10.1016\/j.breast.2013.02.003_bib11","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/S0959-8049(00)00241-0","article-title":"Faslodex (ICI 182780). An oestrogen receptor downregulator","volume":"36","author":"Howell","year":"2000","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.breast.2013.02.003_bib12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1634\/theoncologist.8-4-335","article-title":"Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer","volume":"8","author":"Buzdar","year":"2003","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.breast.2013.02.003_bib13","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0960-9776(03)00137-1","article-title":"Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer","volume":"12","author":"Osborne","year":"2003","journal-title":"Breast"},{"issue":"5","key":"10.1016\/j.breast.2013.02.003_bib14","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2174\/156800910791517226","article-title":"Overcoming endocrine resistance in breast cancer","volume":"10","author":"Madaio","year":"2010","journal-title":"Curr Cancer Drug Targets"},{"issue":"1\u20135","key":"10.1016\/j.breast.2013.02.003_bib15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jsbmb.2005.04.025","article-title":"Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment","volume":"95","author":"Santen","year":"2005","journal-title":"J\u00a0Ster Biochem Mol Biol"},{"issue":"Suppl. 1","key":"10.1016\/j.breast.2013.02.003_bib16","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1677\/erc.1.00992","article-title":"Clinical trials of intracellular signal transductions inhibitors for breast cancer \u2013 a strategy to overcome endocrine resistance","volume":"12","author":"Johnston","year":"2005","journal-title":"Endocr Relat Cancer"},{"issue":"16","key":"10.1016\/j.breast.2013.02.003_bib17","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1101\/gad.1212704","article-title":"Upstream and downstream of mTOR","volume":"18","author":"Hay","year":"2004","journal-title":"Genes Dev"},{"issue":"4","key":"10.1016\/j.breast.2013.02.003_bib18","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/ijc.21932","article-title":"Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells","volume":"119","author":"Beevers","year":"2006","journal-title":"Int J Cancer"},{"issue":"9","key":"10.1016\/j.breast.2013.02.003_bib19","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nrc1974","article-title":"mTOR and cancer: insights into a complex relationship","volume":"6","author":"Sabatini","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1016\/j.breast.2013.02.003_bib20","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc1362","article-title":"The TOR pathway: a target for cancer therapy","volume":"4","author":"Bjornsti","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1016\/j.breast.2013.02.003_bib21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/bcr927","article-title":"New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists","volume":"6","author":"Carraway","year":"2004","journal-title":"Breast Cancer Res"},{"issue":"4","key":"10.1016\/j.breast.2013.02.003_bib22","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3816\/CBC.2006.n.047","article-title":"Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer","volume":"7","author":"Chollet","year":"2006","journal-title":"Clin Breast Cancer"},{"issue":"4","key":"10.1016\/j.breast.2013.02.003_bib23","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","article-title":"A\u00a0functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer","volume":"12","author":"Berns","year":"2007","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.breast.2013.02.003_bib24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccr.2004.06.022","article-title":"PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients","volume":"6","author":"Nagata","year":"2004","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.breast.2013.02.003_bib25","doi-asserted-by":"crossref","first-page":"538","DOI":"10.18632\/oncotarget.302","article-title":"Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy","volume":"2","author":"Sokolosky","year":"2011","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.breast.2013.02.003_bib26","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1158\/0008-5472-CAN-04-3913","article-title":"PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma","volume":"65","author":"Saal","year":"2005","journal-title":"Cancer Res"},{"issue":"18","key":"10.1016\/j.breast.2013.02.003_bib27","doi-asserted-by":"crossref","first-page":"10314","DOI":"10.1073\/pnas.171076798","article-title":"Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP\/mTOR","volume":"98","author":"Neshat","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.breast.2013.02.003_bib28","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1677\/erc.0.0080249","article-title":"mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer","volume":"8","author":"Yu","year":"2001","journal-title":"Endocr Rel Cancer"},{"issue":"29","key":"10.1016\/j.breast.2013.02.003_bib29","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1038\/onc.2011.42","article-title":"PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs","volume":"30","author":"Weigelt","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.breast.2013.02.003_bib30","first-page":"A5619","article-title":"The mTOR pathway in estrogen response: a potential for combining the rapamycin derivative RAD001 with the aromatase inhibitor letrozole in breast carcinomas","volume":"45","author":"Rudloff","year":"2004","journal-title":"Proc Am Assoc Cancer Res"},{"issue":"10","key":"10.1016\/j.breast.2013.02.003_bib31","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1093\/annonc\/mdh388","article-title":"Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase\/Akt pathway","volume":"15","author":"de Graffenried","year":"2004","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.breast.2013.02.003_bib32","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/annonc\/mdm170","article-title":"Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling","volume":"18","author":"Beeram","year":"2007","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.breast.2013.02.003_bib33","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1158\/1078-0432.CCR-04-2402","article-title":"Dual inhibition of mTOR and estrogen receptor signaling in\u00a0vitro induces cell death in models of breast cancer","volume":"11","author":"Boulay","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2013.02.003_bib34","doi-asserted-by":"crossref","unstructured":"Carpenter JT, Roche H, Campone M, et\u00a0al. Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. Presented at the 2005 ASCO annual meeting, Orlando, FL; May 13\u201315, 2005.","DOI":"10.1200\/jco.2005.23.16_suppl.564"},{"issue":"2","key":"10.1016\/j.breast.2013.02.003_bib35","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1200\/JCO.2011.38.3331","article-title":"Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer","volume":"31","author":"Wolff","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2013.02.003_bib36","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejca.2007.10.003","article-title":"The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics","volume":"44","author":"Awada","year":"2008","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.breast.2013.02.003_bib37","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2013.02.003_bib38","unstructured":"Hortobagyi GN, Piccart M, Rugo H, et\u00a0al. Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO 2 phase III trial. Presented at the 34th annual San Antonio breast cancer symposium, San Antonio, TX; December 6\u201310, 2011."},{"key":"10.1016\/j.breast.2013.02.003_bib39","unstructured":"Piccart M, Noguchi S, Pritchard KI, et\u00a0al. Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO-2 phase III trial. 6-1-2012. Presented at the American Society of Clinical Oncology annual meeting, Chicago, Illinois; June 1\u20135, 2012."},{"key":"10.1016\/j.breast.2013.02.003_bib40","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2011.39.0708","article-title":"Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study","volume":"30","author":"Bachelot","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.breast.2013.02.003_bib41","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1200\/JCO.2008.18.8391","article-title":"Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer","volume":"27","author":"Baselga","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2013.02.003_bib42","unstructured":"Badin F, Romond E, Chambers M, et\u00a0al. A phase II trial of fulvestrant and RAD001 (everolimus) in patients with metastatic estrogen receptor positive breast cancer after aromatase inhibitor failure; a study in progress. Presented at the 33rd annual San Antonio breast cancer symposium, San Antonio, TX; December 8\u201312, 2010."},{"key":"10.1016\/j.breast.2013.02.003_bib43","doi-asserted-by":"crossref","unstructured":"Rugo HS, Pritchard KI, Gnant M, et\u00a0al. Everolimus (EVE) for postmenopausal women with advanced breast cancer (ABC) refractory to letrozole or anastrozole: long-term efficacy and safety results of the BOLERO-2 trial. Presented at the 8th European breast cancer conference, Vienna, Austria; March 21\u201324, 2012.","DOI":"10.1016\/S0959-8049(12)70320-9"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977613000349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977613000349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:31:36Z","timestamp":1760776296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977613000349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0960977613000349"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2013.02.003","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Everolimus in hormone receptor\u2013positive advanced breast cancer: Targeting receptor-based mechanisms of resistance","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2013.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}